Question special
Chief Resident

The study introduces a major step forward in lipid management. It encourages all physicians to reassess their approach to assessment and management of clinic patients presenting high LDL-cholesterol levels despite maximum standard of care therapies.
Incredibly robust efficacy performance measures of the investigational agent at completion of 16 weeks of active drug administration. The reported changes in LDL-Cholesterol are particularly robust when considering the Inclusion Criteria for the study. Patients 18-80 years of age were eligible if they had primary HFH or non-heterozygous HFH with atherosclerotic disease, but one of the limitations of the study is that the racial background was not as diverse as intended. What were some of the challenges in achieving a more diverse sample?